Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenn…
Biotechnology
US, Waltham [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Dyne Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2023 | -3.1800 | -3.784 | 0 | 0 | -165 | -225 | -164 | 0 | -174 | 0 | 28 | 0 |
| 2024 | -3.9500 | -3.468 | 0 | 0 | -235 | -206 | -233 | 0 | -244 | 0 | 31 | 0 |
| 2025 | - | -3.768 | - | 0.83 | - | -225 | - | 0 | - | 0 | - | 0 |
| 2026 | - | -3.864 | - | 9 | - | -241 | - | 0 | - | 0 | - | 0 |
| 2027 | - | -3.258 | - | 192 | - | 1.F4X/td> | - | 1.F41/td> | - | 1.F41 | - | 1.F41 |
| 2028 | - | -1.160 | - | 500 | - | 0.F5X/td> | - | 0.F51/td> | - | 0.F51 | - | 0.F51 |